Interview, Fireside Chat
Inside Moderna’s Biggest mRNA Test Since COVID
- Moderna and Merck announced positive results from a Phase 3 clinical trial for a personalized mRNA cancer vaccine (Intismoran) in patients with melanoma.
- This marks the first time in over 20 years and more than 1,000 failed clinical trials that an individualized cancer vaccine has demonstrated efficacy superior to the current standard of care.
- The trial met its primary endpoint: recurrence-free survival, and unexpectedly met its secondary endpoint: distant metastasis-free survival during the first interim analysis.
- Phase 2 data demonstrated that 80% of patients were disease-free five years post-treatment and surgery, compared to 50% for patients treated with Keytruda alone; five years is considered a clinical benchmark for a "cure."
- The vaccine is administered as an adjuvant therapy alongside Merck's PD-1 inhibitor, Keytruda, which alone leaves 40% of patients with no disease-free survival and carries a high risk of severe autoimmune side effects.
- Unlike Keytruda, which "unleashes" the immune system non-specifically, the mRNA vaccine teaches the immune system to identify and attack specific cancer antigens unique to the patient.
- The manufacturing process involves a "needle-to-needle" turnaround time of approximately 42 days, during which a tumor biopsy is sequenced and compared to healthy cell DNA to identify relevant mutations.
- An algorithm selects roughly 34 relevant mutations from the hundreds found in a patient's tumor to be synthesized into a single mRNA molecule.
- Approximately 90% of cancer antigens differ from patient to patient, necessitating a fully individualized approach rather than a "one-size-fits-all" vaccine targeting shared antigens.
- Moderna is refining its proprietary algorithm (version 1.0) using Phase 3 patient data to improve efficacy for the 20% of patients who did not respond to the initial treatment iteration.
- The production process is fully synthetic and enzymatic, allowing for smaller reactor volumes and higher throughput compared to the cell-based manufacturing required for CAR-T therapies.
- A dedicated facility in Marlboro, Massachusetts, is currently capable of producing tens of thousands of doses annually, with plans to scale further if demand increases.
- Regulatory approval is pursued via a "process BLA" (Biologics License Application), similar to CAR-T therapies, rather than a product-specific BLA, acknowledging that every dose is unique.
- The company plans to file for regulatory approval with the FDA soon, targeting patient availability in 2027 pending final data review.
- Moderna is expanding clinical trials to other indications where Keytruda is effective, including Phase 3 studies for lung cancer and Phase 2 studies for kidney and bladder cancer.
- A Phase 3 study has been initiated for Stage 1 lung cancer where the vaccine will be used as a monotherapy to avoid the side effects of checkpoint inhibitors in early-stage disease.
- Research is underway to apply the technology to "cold" tumors where immunotherapy fails, specifically pancreatic and gastric cancers, potentially in combination with other agents.
- Future pipeline expansion includes targeting rare genetic diseases in children, with Phase 1/2 data showing promising results for liver diseases.
- Moderna is investigating the mRNA platform for autoimmune diseases, with a potential future focus on personalized treatments that target the root cause rather than symptoms.
- Stéphane Bancel emphasized that the current algorithm represents the "worst version" the company will ever see, driven by a commitment to continuous improvement using AI and deeper data mining.
- The company aims to industrialize the manufacturing process to make personalized vaccines safer and more accessible than patient-specific, in-hospital fabrication methods.